Last reviewed · How we verify

NCT06675708: SECPFMAPFM

Effectiveness of Creatine on Pain, Fatigue, and Muscle Architectural Variables in Patients Witg Fibromyalgia.

ENROLLING BY INVITATION NA Last updated 1 July 2025
What this trial tests

NA trial testing Creatine in Fibromyalgia in 80 participants. Enrolling by invitation.

Timeline
12 February 2025
Primary endpoint
30 May 2026
30 June 2026

Quick facts

Lead sponsorCamilo Jose Cela University
PhaseNA
StatusENROLLING BY INVITATION
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingtriple
Primary purposeother
Enrollment80
Start date12 February 2025
Primary completion30 May 2026
Estimated completion30 June 2026
Sites1 location across Spain

Drugs / interventions tested

Conditions studied

Sponsor

Camilo Jose Cela University

Who can join

Adults 18 to 75, any sex, with Fibromyalgia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Creatine, a non-protein organic amino acid, is synthesized from arginine, glycine, and methionine. The use of creatine has been shown to be effective in healthy subjects, providing benefits primarily in terms of strength, which has been the main factor studied. In patients with various conditions, including pain, creatine supplementation has demonstrated a reduction in pain and even cognitive improvements. Due to creatine's general improvement in muscular endurance and fatigue.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Creatine

Trials testing the same drug.

Other recruiting trials for Fibromyalgia

Currently open trials in the same condition.

Other Camilo Jose Cela University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06675708.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing